MSD Deploys AI To Accelerate Drug Discovery
In an interview, Anton Groom, chief AI officer at MSD, describes how the company is deploying AI across drug discovery, clinical development and manufacturing, naming models such as TEDDY and KERMT. He says AI has doubled the number of molecules in development and produced two candidates now in clinical trials, while emphasizing human-in-the-loop oversight and bias mitigation. MSD plans to impact all near-term drug opportunities with supplier-agnostic, safety-focused AI.
Key Points
- 1Deploys models TEDDY and KERMT alongside scientists, producing two molecules now in clinical trials.
- 2Positions AI as a talent multiplier and predictivity booster, doubling molecules and compressing discovery timelines.
- 3Implements human-in-the-loop oversight, supplier-agnostic architecture and bias-testing to ensure regulatory safety and trust.
Scoring Rationale
Strong company-level deployment and measurable pipeline gains; limited novelty beyond one-company case and few technical details.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
